"Fat necrosis following deep inferior epigastric artery perforator flap breast reconstruction: A systematic review and meta-analysis".

J Plast Reconstr Aesthet SurgJul 20, 2026 (epub)
Clinical ResearchPlastic SurgeryGeneral Surgery

Karanvir S Raman, Arjin Akdag, Sara B A Morel et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined factors influencing fat necrosis in Deep Inferior Epigastric Artery Perforator (DIEP) flap breast reconstructions, analyzing data from 100 studies involving 9704 flaps. The study found that intraoperative indocyanine green fluorescence significantly reduced fat necrosis risk (RR 0.64, 95% CI 0.49-0.83, P=0.0008).

Key findings

  • Intraoperative indocyanine green fluorescence reduced fat necrosis risk (RR 0.64, 95% CI 0.49-0.83, P=0.0008).
  • Flaps based on lateral row perforators had a lower risk of fat necrosis (RR 0.59, 95% CI 0.43-0.82, P=0.001).
  • Harvesting ≥2 perforators decreased fat necrosis risk (RR 0.68, 95% CI 0.48-0.96, P=0.03).
  • Unilateral reconstructions increased fat necrosis risk (RR 1.53, 95% CI 1.13-2.06, P=0.006).

Why it matters

Understanding the predictors of fat necrosis in DIEP flap reconstructions is crucial for improving surgical outcomes and patient counseling. This knowledge can help clinicians optimize surgical techniques and manage patient expectations regarding recovery and aesthetic results.

Source

PubMed · PMID 42501419

Published in J Plast Reconstr Aesthet Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Plastic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.